Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissue

19 Sept 2023

Abstract excerpt

PURPOSE: BRCA-deficient breast cancers (BC) are highly sensitive to platinum-based chemotherapy and PARP inhibitors due to their deficiency in the homologous recombination (HR) pathway. However, HR deficiency (HRD) extends beyond BRCA-associated BC, highlighting the need for a sensitive method to enrich for HRD tumors in an alternative way. A promising approach is the use of functional HRD tests which evaluate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Breast Cancer Treatment Studies
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37725154
DOI: 10.1007/s10549-023-07102-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissuePMID 37725154Read ↗

The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor BlocksSemantic proximity Read ↗

Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene DefectsSemantic proximity Read ↗

RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?Semantic proximity Read ↗

Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness testsSemantic proximity Read ↗

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient StratificationSemantic proximity Read ↗

The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian CarcinomasSemantic proximity Read ↗

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationSemantic proximity Read ↗

Functional <i>Ex Vivo</i> Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor TreatmentSemantic proximity Read ↗

Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.Semantic proximity Read ↗

Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-ProficientSemantic proximity Read ↗

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.Semantic proximity Read ↗

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.